Fragment-based discovery of JAK-2 inhibitors

被引：69

作者：

Antonysamy, Stephen ^{[1
]}

Hirst, Gavin ^{[1
]}

Park, Frances ^{[1
]}

Sprengeler, Paul ^{[1
]}

Stappenbeck, Frank ^{[1
]}

Steensma, Ruo ^{[1
]}

Wilson, Mark ^{[1
]}

Wong, Melissa ^{[1
]}

机构：

[1] SGX Pharmaceut Inc, Med Chem, San Diego, CA 92121 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2009年 / 19卷 / 01期

关键词：

Fragment-based design; JAK-2; inhibitors; Structure-based design; Aminoindazole; Kinase inhibitors; MYELOPROLIFERATIVE DISORDERS; JAK/STAT PATHWAY; STATS;

D O I：

10.1016/j.bmcl.2008.08.064

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Fragment-based hit identification coupled with crystallographically enabled structure-based drug design was used to design potent inhibitors of JAK-2. After two iterations from fragment 1, we were able to increase potency by greater than 500-fold to provide sulfonamide 13, a 78-nM JAK-2 inhibitor. (C) 2008 Published by Elsevier Ltd.

引用

页码：279 / 282

页数：4

共 10 条

[1] Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis
Brameld, Ken A.
Kuhn, Bernd
Reuter, Deborah C.
Stahl, Martin
[J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2008, 48 (01) : 1 - 24
[2] Recent developments in fragment-based drug discovery
Congreve, Miles
Chessari, Gianni
Tisi, Dominic
Woodhead, Andrew J.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (13) : 3661 - 3680
[3] Oncogenic mechanisms in myeloproliferative disorders
Delhommeau, F.
Pisani, D. F.
James, C.
Casadevall, N.
Constantinescu, S.
Vainchenker, W.
[J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2006, 63 (24) : 2939 - 2953
[4] Signaling through the JAK/STAT pathway, recent advances and future challenges
Kisseleva, T
Bhattacharya, S
Braunstein, J
Schindler, CW
[J]. GENE, 2002, 285 (1-2) : 1 - 24
[5] JAKS AND STATS: Biological implications
Leonard, WJ
O'Shea, JJ
[J]. ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 : 293 - 322
[6] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Levine, RL
Wadleigh, M
Cools, J
Ebert, BL
Wernig, G
Huntly, BJP
Boggon, TJ
Wlodarska, L
Clark, JJ
Moore, S
Adelsperger, J
Koo, S
Lee, JC
Gabriel, S
Mercher, T
D'Andrea, A
Fröhling, S
Döhner, K
Marynen, P
Vandenberghe, P
Mesa, RA
Tefferi, A
Griffin, JD
Eck, MJ
Sellers, WR
Meyerson, M
Golub, TR
Lee, SJ
Gilliland, DG
[J]. CANCER CELL, 2005, 7 (04) : 387 - 397
[7] A Src-like inactive conformation in the Abl tyrosine kinase domain
Levinson, Nicholas M.
Kuchment, Olga
Shen, Kui
Young, Matthew A.
Koldobskiy, Michael
Karplus, Martin
Cole, Philip A.
Kuriyan, John
[J]. PLOS BIOLOGY, 2006, 4 (05) : 753 - 767
[8] STATs: Transcriptional control and biological impact
Levy, DE
Darnell, JE
[J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (09) : 651 - 662
[9] Cytokine signaling in 2002: New surprises in the Jak/Stat pathway
O'Shea, JJ
Gadina, M
Schreiber, RD
[J]. CELL, 2002, 109 : S121 - S131
[10] JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
Pardanani, A.
[J]. LEUKEMIA, 2008, 22 (01) : 23 - 30

← 1 →